Last reviewed · How we verify

NCT06316362

Efficacy of SMOF Lipid in the Management of Acute Poisoning With Carbamazepine

Completed Phase 2 Last updated 10 October 2024
What this trial tests

Phase 2 trial testing SMOF lipid 20% in Acute Poisoning in 40 participants. Completed in 28 February 2023.

Timeline
1 January 2022
Primary endpoint
1 February 2023
28 February 2023

Quick facts

Lead sponsorAlexandria University
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment40
Start date1 January 2022
Primary completion1 February 2023
Estimated completion28 February 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Alexandria University

Who can join

Adults 18 to 54, any sex, with Acute Poisoning. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of the current study was to evaluate whether SMOF lipid administration could be used as an adjuvant therapy to treat acute, moderate-to-severe carbamazepine poisoning.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of SMOF lipid 20%

Trials testing the same drug.

Other recruiting trials for Acute Poisoning

Currently open trials in the same condition.

Other Alexandria University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06316362.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing